ImpediMed's FY20 first-half result met the broker, the company posting a net loss of $12.9m, and retaining the equivalent in cash reserves.

Solid growth was logged in SOZO revenue with 90,000 patient tests having been completed since the launch. The company also notes progress in the heart failure program.

The major catalyst remains a decision by the National Comprehensive Cancer Network to include the company's technology in its cancer treatment guidelines, but the outcome is anyone's guess.

Forecasts are unchanged. Speculative Buy maintained. Target price steady at 26c.

Sector: Health Care Equipment & Services.

Target price is $0.26.Current Price is $0.11. Difference: $0.15 - (brackets indicate current price is over target). If IPD meets the Morgans target it will return approximately 58% (excluding dividends, fees and charges - negative figures indicate an expected loss).

© 2020 Acquisdata Pty Ltd., source FN Arena